Eliana Merle Analyst PerformanceAnalyst at BarclaysEliana Merle is a stock analyst at Barclays focused in the medical sector, covering 36 publicly traded companies. Over the past year, Eliana Merle has issued 60 stock ratings, including strong buy, buy, hold, and sell recommendations. While full access to Eliana Merle's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eliana Merle's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings113 Last 7 YearsBuy Recommendations80.37% 86 Buy RatingsCompanies Covered36 Unique Companies Ratings Distribution107RatingsDistribution of strong buy, buy, hold, and sell ratings by Eliana Merle.RatingPercentageCount Strong Buy0.9%0 ratings Buy79.4%85 ratings Hold18.7%20 ratings Sell0.9%0 ratingsOut of 107 total stock ratings issued by Eliana Merle at Barclays, the majority (79.4%) have been Buy recommendations, followed by 18.7% Hold, 0.9% Strong Buy, and 0.9% Sell.Best & Worst CallsBest Call0000.0%KYMRMay 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ANABNov 2018Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ36 companiesEliana Merle, an analyst at Barclays, currently covers 36 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical34 companies94.4%Manufacturing1 company2.8%Finance1 company2.8%Eliana Merle of Barclays specializes in stock coverage within the Medical sector, with additional focus on Manufacturing and Finance companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE27 companies75.0%MED - DRUGS5 companies13.9%PHARMACEUTICAL PREPARATIONS2 companies5.6%MED - GENERIC DRG1 company2.8%FIN - INVEST MGMT1 company2.8% Eliana Merle's Ratings History at Barclays Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsMBXMBX Biosciences5/12/2026Boost Price Target$40.08$70.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S5/11/2026Boost Price Target$238.66$345.00Overweight$0.0000.00% ROIVRTXVertex Pharmaceuticals5/6/2026Boost Price Target$424.36$615.00Overweight$0.0000.00% ROIMRNAModerna5/4/2026Boost Price Target$47.45$45.00Neutral$0.0000.00% ROIIONSIonis Pharmaceuticals4/30/2026Boost Price Target$74.83$115.00Overweight$0.0000.00% ROIREGNRegeneron Pharmaceuticals4/30/2026Lower Price Target$705.68$917.00Overweight$0.0000.00% ROIRAREUltragenyx Pharmaceutical4/29/2026Lower Price Target$24.35$43.00Overweight$0.0000.00% ROIMRNAModerna4/2/2026Boost Price Target$48.85$48.00Equal Weight$0.0000.00% ROIAPLSApellis Pharmaceuticals4/1/2026Boost Price Target$40.40$41.00Equal Weight$0.0000.00% ROIINSMInsmed4/1/2026Boost Price Target$164.74$237.00Overweight$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. IONSIonis Pharmaceuticals3/26/2026Boost Price Target$72.70$106.00Overweight$0.0000.00% ROIQUREuniQure3/23/2026Lower Price Target$15.88$25.00Equal Weight$0.0000.00% ROIBBIOBridgeBio Pharma3/10/2026Reiterated Rating$74.32Overweight$0.0000.00% ROIREGNRegeneron Pharmaceuticals3/6/2026Initiated Coverage$764.93$923.00Overweight$0.0000.00% ROITPGTPG3/2/2026Lower Price Target$43.49$56.00Overweight$0.0000.00% ROIGOSSGossamer Bio2/24/2026Downgrade$0.42Underweight$0.0000.00% ROIPTCTPTC Therapeutics2/23/2026Reiterated Rating$70.66$120.00Overweight$0.0000.00% ROIVRTXVertex Pharmaceuticals2/17/2026Boost Price Target$491.47$607.00Overweight$0.0000.00% ROIMRNAModerna2/16/2026Reiterated Rating$42.23$36.00Neutral$0.0000.00% ROITPGTPG2/6/2026Set Price Target$53.54$69.00$0.0000.00% ROIAPLSApellis Pharmaceuticals1/28/2026Initiated Coverage$21.81$24.00Equal Weight$0.0000.00% ROIBBIOBridgeBio Pharma1/28/2026Initiated Coverage$77.87Overweight$0.0000.00% ROIQUREuniQure1/27/2026Initiated Coverage$24.37$31.00Equal Weight$0.0000.00% ROITYRATyra Biosciences1/27/2026Initiated Coverage$31.40Overweight$0.0000.00% ROISGMTSagimet Biosciences1/27/2026Initiated Coverage$6.09$8.00Equal Weight$0.0000.00% ROIMBXMBX Biosciences1/27/2026Initiated Coverage$36.07$66.00Overweight$0.0000.00% ROIMDGLMadrigal Pharmaceuticals1/27/2026Initiated Coverage$500.39$964.00Overweight$0.0000.00% ROIKYMRKymera Therapeutics1/27/2026Boost Price Target$72.15$133.00Overweight$0.0000.00% ROIIVAInventiva1/27/2026Initiated Coverage$6.87$18.00Overweight$0.0000.00% ROIINSMInsmed1/27/2026Initiated Coverage$162.64$231.00Overweight$0.0000.00% ROIGOSSGossamer Bio1/27/2026Initiated Coverage$2.64$9.00Overweight$0.0000.00% ROIASNDAscendis Pharma A/S1/27/2026Initiated Coverage$238.80$342.00Overweight$0.0000.00% ROIAPLSApellis Pharmaceuticals1/27/2026Upgrade$23.07Hold$0.0000.00% ROIASNDAscendis Pharma A/S1/27/2026Initiated Coverage$222.45$342.00Overweight$0.0000.00% ROIGOSSGossamer Bio1/27/2026Initiated Coverage$2.55$9.00Overweight$0.0000.00% ROIINSMInsmed1/27/2026Initiated Coverage$155.89$231.00Overweight$0.0000.00% ROIIVAInventiva1/27/2026Initiated Coverage$6.83$18.00Overweight$0.0000.00% ROIMBXMBX Biosciences1/27/2026Initiated Coverage$35.83$66.00Overweight$0.0000.00% ROIMDGLMadrigal Pharmaceuticals1/27/2026Initiated Coverage$496.54$964.00Overweight$0.0000.00% ROIQUREuniQure1/27/2026Upgrade$23.02Hold$0.0000.00% ROIIran's New Leader Just Said Something That Should Terrify Every American (Ad)Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.Claim your free copy of The Great Gold Reset report todaySGMTSagimet Biosciences1/27/2026Upgrade$5.86Hold$0.0000.00% ROIMRNAModerna1/6/2026Downgrade$35.66$34.00Neutral$0.0000.00% ROIMDGLMadrigal Pharmaceuticals12/19/2025Set Price Target$544.41$900.00$0.0000.00% ROIMDGLMadrigal Pharmaceuticals12/4/2025Upgrade$568.57Strong-Buy$0.0000.00% ROIMRNAModerna11/21/2025Reiterated Rating$23.47Buy$0.0000.00% ROIMRNAModerna11/21/2025Set Price Target$23.07$18.00$0.0000.00% ROIMRNAModerna10/23/2025Lower Price Target$26.85$40.00Buy$0.0000.00% ROIBBIOBridgeBio Pharma9/12/2025Boost Price Target$52.77$82.00Buy$0.0000.00% ROIALTAltimmune8/13/2025Lower Price Target$3.85$24.00Buy$0.0000.00% ROIRAPTRapt Therapeutics8/12/2025Set Price Target$9.52$9.00Neutral$0.0000.00% ROIMDGLMadrigal Pharmaceuticals8/12/2025Reiterated Rating$350.83$523.00Buy$0.0000.00% ROIANABAnaptysBio8/12/2025Reiterated Rating$20.10$20.00Neutral$0.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Reiterated Rating$183.33$307.00Buy$0.0000.00% ROIBMRNBioMarin Pharmaceutical8/5/2025Boost Price Target$60.31$114.00Buy$0.0000.00% ROIALNYAlnylam Pharmaceuticals8/1/2025Boost Price Target$398.49$550.00Buy$0.0000.00% ROISRPTSarepta Therapeutics7/21/2025Reiterated Rating$13.56Neutral$0.0000.00% ROIPROKProKidney7/15/2025Boost Price Target$3.84$8.00Buy$0.0000.00% ROICVACCureVac6/26/2025Downgrade$5.42$5.50Neutral$0.0000.00% ROIRAPTRapt Therapeutics5/22/2025Lower Price Target$7.10$8.00Neutral$0.0000.00% ROIARVNArvinas5/15/2025Lower Price Target$5.93$21.00Buy$0.0000.00% ROIKYMRKymera Therapeutics5/13/2025Lower Price Target$31.02$70.00Buy$00.0000.00% ROIMRNAModerna5/2/2025Lower Price Target$27.61$70.00Buy$00.0000.00% ROIMDGLMadrigal Pharmaceuticals5/2/2025Boost Price Target$315.48$458.00Buy$000.0000.00% ROIBBIOBridgeBio Pharma4/30/2025Boost Price Target$38.57$72.00Buy$00.0000.00% ROICVACCureVac4/30/2025Lower Price Target$3.65$12.00Buy$0.0000.00% ROIAPLSApellis Pharmaceuticals4/29/2025Initiated Coverage$17.96$44.00Overweight$00.0000.00% ROIBMRNBioMarin Pharmaceutical2/20/2025Boost Price Target$67.92$113.00Buy$00.0000.00% ROIMRNAModerna2/19/2025Lower Price Target$36.15$78.00Buy$00.0000.00% ROIETNB89BIO1/31/2025Boost Price Target$9.44$38.00Buy$0.0000.00% ROIAKROAkero Therapeutics1/31/2025Boost Price Target$53.43$109.00Buy$0.0000.00% ROIZNTLZentalis Pharmaceuticals1/28/2025Lower Price Target$2.38$2.20Neutral$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
